Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries

Accepted/In Press date: 2022

e-pub ahead of print date: 22 September 2022

Published date: 22 September 2022

Additional Information: Funding Information: The ALIC4E trial and the contributions of AWV, SC, EB, MDP, SCh, MGC, NF, RA, HCB, AC, ADS, AGS, DG, NJH, KK, ML, CL, CaL, RMP, RRJ, BS, PDS, PTL, NT, TJV, HG, CCB and PB were funded by the European Commission’s Seventh Framework Programme: Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE) (grant HEALTH-F3-2013-602525). PB, XL, JB and RB acknowledge partial Methusalem funding from the VAX-IDEA and ASCID Centres of Excellence in vaccination and infectious diseases at the University of Antwerp. JB and RB were funded by their personal postdoctoral grants from the Research Foundation—Flanders (FWO). PDS acknowledges that The Healthcare Committee, Region Västra Götaland, Sweden, partially funded the Swedish part of the study. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. Funding Information: CCB reports grants from National Institute for Health Research Health and grants from National Institute for Health Research Health Protection Research Unit on Health Care Associated Infections and Antimicrobial Resistance during the conduct of the study; personal fees from Roche Molecular Systems, grants from Roche Molecular Diagnostics, personal fees from Pfizer, personal fees from Roche diagnostics, personal fees from Janssen Pharmaceuticals, outside the submitted work. DG reports to be employed since June 1, 2020, by Roche Pharma (Schweiz) AG, Basel, Switzerland. Data collections for this manuscript have been completed before his current employment. PB reports grants from European commission IMI, outside the submitted work. NF reports grants from NIHR and Synairgen, consultancy fees from GSK, presenters fees from Abbott and holding stock of Synairgen and AstraZeneca, outside of this submitted work. PDS declares that the Healthcare Committee, Region Västra Götaland, Sweden, partially funded the Swedish part of the study. CL reports grants from Oxford University outside of the submitted work. All other authors declare no competing interests. Publisher Copyright: © 2022, The Author(s).

Keywords: Cost-utility analysis, Direct cost, Europe, ILI, Indirect cost, Multi-country, Productivity losses, QALY, Tamiflu

Local EPrints ID: 470900

URI: http://eprints.soton.ac.uk/id/eprint/470900

DOI: doi:10.1007/s10198-022-01521-2

ISSN: 1618-7598

PURE UUID: 9cb07f85-e90f-46e8-b690-734b793e6253

ORCID for Nick Francis: orcid.org/0000-0001-8939-7312

Date deposited: 20 Oct 2022 16:51

Last modified: 17 Mar 2024 03:58